ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VRP Verona Pharma Plc

55.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 55.00 45.00 65.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Verona Pharma Share Discussion Threads

Showing 12351 to 12372 of 13325 messages
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older
DateSubjectAuthorDiscuss
16/3/2016
19:05
Yesterdays gains given back and more. This share really is unloved. I have held for two years and am no further in understanding why it is so lowly rated. I agree with the comments above on funding perhaps weighing this down but thought that would be more than counterbalanced by the possibility of a bigger player having a look at the latest rns. Hey ho, patience definitely the name of the game here.
fozzie
16/3/2016
13:56
The top line results from the asthma study announced yesterday could not have been much better, yet the share price reaction has been disappointing, presumably this is down to funding concerns?

It was good to hear that the SABA combo study will now report in Q2 (rather than Q3), I suspect the combo study is the one which will generate the most interest so far with potential partners, especially if we see an additive (or synergistic) effect with the SABA.

There must be a good chance that we hear about future funding proposals with the combo results (especially if they are good!)

timbo003
16/3/2016
11:21
Verona Pharma Source: Fidessa
Market data EPIC/TKR
Price (p)
12m High (p) 12m Low (p) Shares (m)
Mkt Cap (£m) EV (£m)
Free Float* Market
VRP 4.0 6.2 1.0
1009.9 40.4 34.3 58% AIM
*As defined by AIM Rule 26
Description Verona Pharma plc is a UK-based biopharmaceutical company focused on development of innovative prescription drugs to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma & cystic fibrosis
Company information CEO CFO
Chairman
Jan-Anders Karlsson Biresh Roy
David Ebsworth 0203 283 4200
www.veronapharma.com
Key shareholders Directors Arthurian Aviva
Fidelity Vivo Capital
Next event 11 June
2Q'16 Sept
4Q'16 2.9%
20.8% 18.0% 7.6% 6.4%
De-risking of RPL554 continues VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced by existing drugs. Four out of five trials in the clinical development programme have been completed with positive outcomes, with the fifth due to report in 2Q’16. To date, RPL554 has been shown to have a strong bronchodilatory effect with minimal side effects and will certainly be attracting the attention of drug majors. Median prices paid for Phase II respiratory assets have headline valuations of $285m (£190m), equivalent to 19p per share.
► RPL554 in asthma: VRP has reported positive outcomes from a Phase IIa trial of nebulised RPL554 in 29 mild-to-moderate asthma patients which commenced in June 2015 and was fully recruited by early November 2015. This complex crossover study compared RPL554 with two doses of salbutamol, or placebo.
► Outcome: The bronchodilatory effect of RPL554 was equivalent to that seen with the highest dose of nebulised salbutamol used to treat an asthma attack. No GI side effects or CV effects of concern were observed. These results suggest that RPL554 could be a useful addition for treating respiratory disease.
► Results: A more complete data set will be presented at a respiratory conference in May, by which time, Verona is also likely to have released data from its Phase IIa trial in COPD patients to identify if RPL554 has an additive broncholdilatory effect. These trials are all contributing significantly to the de-risking of RPL554.
► Valuation: About £18m has been invested in R&D to get VRP where it is today, compared to an EV of £34m. This positive outcome, coupled with the potential Phase IIa results in COPD, represents a major value inflection point and will progress the interest of the drug majors towards a commercial licensing deal.
► Investment summary: Historically, efficacy of PDE inhibitors has been positive, but putative drugs have failed due to side effects. To date, results with the new formulation of RPL554 have exceeded expectations, which augurs well for the pivotal Phase IIb trial due to start in early 2017. With big pharma constantly searching for new respiratory assets, RPL554 will definitely be on the radar.

thebossman
16/3/2016
10:46
Still think the share price reaction was rather muted compared to say GW Pharma.
difficult to see why there would be sellers -unless people think a dilutive placing may be on the cards. Looks to be a good long term hold I think.
I note one of the Hardman analysts is new- from the previous note.

meijiman
16/3/2016
10:38
I've been in these since April 2010 - I have a lot know (what with all the averaging)....
tomgreg
16/3/2016
10:36
Thanks Vas, Was wondering about the wording of the rns yesterday, albeit an excellent rns, the mention of formula tested matching salbutomol? (was it suggesting the fev1 curve was better than Salbutomol? as per previous graph that showed fev1 and duration? (for twice nebbing over 24 hours) the latency period was good.
yesterdays rns didnt say in terms of bettering? even tho the sides (lack of) were hugely important.
Maybe this has fev1 data not released has been the causation of holding the share price from gaining more traction and interest?
we know earlier results showed 554 beating salbutomol not just for immediate relief but for latency-duration too.
Also im keen to see results of future trials where 554 is tested alone as well as dualled with some of the current regime out there to see if there are also double win win benefits?
regards
Corbs:-)
thanks for hardman- if not already over on lse chat-i will borrow and post :-)

corbine
16/3/2016
09:04
I see that Hardman has updated its report :-



Note the comment made under 'Results' - 'A more complete data set will be presented at a respiratory conference in May, by which time, Verona is also likely to have released data from its Phase IIa trial in COPD patients to identify if RPL554 has an additive broncholdilatory effect. These trials are all contributing significantly to the de-risking of RPL554.'

Corbs - I presume that the data set will include FEV1 results but if not the subject will probably come up at the AGM in June.

Also, I think that we can take it from the above statement that results from the next trial are expected in the first half of Q2 - and also expected to be positive bearing in mind the strength of yesterday's results using the new formulation.

vasilis
15/3/2016
17:50
Tom -all in good time-the rns was good and there is more to follow.
:-)

corbine
15/3/2016
15:25
That flurry of excitement was short lived....
tomgreg
15/3/2016
11:43
Can anyone tell me why this share has not rocketed? I believe with this news this share should be 10p+... Or ppl just taking 5-10% profits n holding this down... Im new to this share.. Any comment would be much appreciated thanks
alexalex7
15/3/2016
11:42
Verona Pharma
De-risking of RPL554 continues

VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced by existing drugs. Four out of five trials in the clinical development programme have been completed with positive outcomes, with the fifth due to report in 2Q’16. To date, RPL554 has been shown to have a strong bronchodilatory effect with minimal side effects and will certainly be attracting the attention of drug majors. Median prices paid
for Phase II respiratory assets have headline valuations of $285m (£190m), equivalent to 19p per share

aishah
15/3/2016
10:52
Not forgetting they mention asthma market being 1 billion, note they are only mentioning currently emergency admissions.
with safety now significantly derisked and the twice daily dosing, vrp have also previously mentioned the 554 compound can be used as a maintenance dose.
this can now be worked on so market is multifold (billions) that already quoted for just asthma,
554 can and will be used in home settings for asthma and also copd to prevent exacerbations as well as treating exacerbations whereas patients currently neb with both ventolin and ipratropium bromide, now they can neb with a single solution doing both jobs without side effects.
dont forget this is talking about atomised neb solutions, whereas future use they will be able to work on dry powder, hand held inhalers doing same job for maintenance for copd and asthma as well as nebbed copd solutions.
this is awesome news and as expected.
id still like to see vrp share the fev1 curve (gold standard) data with investors and wider public with lineage on full pft overlaid as well with additional marker dots showing where the small tolerable sides were reported, this can then be used for the world to see for investors as well as the big pharmas who will be clearly taking note.
over 200 variants of 554 molecule and here we are, knocking down the current drug regime and note breo which is new has some really bad side effects so roll on 554.
2 more sets of news due shortly.
all imo jmo gl dyoR etc
Happy Corbs :-)

corbine
15/3/2016
08:42
This paragraph in the RNS contains the 'golden nuggets' -

'The study met its primary objective, with nebulised RPL554 demonstrating a
dose-dependent bronchodilator response in asthma patients. RPL554
pharmacokinetics were linear across the whole dose range. At the highest doses
of both compounds, RPL554 produced the same maximum bronchodilator effect as
salbutamol. Even the lowest RPL554 dose of 0.4mg was significantly superior (p
<0.0001) to placebo as a bronchodilator. All doses of RPL554 were found to be
well tolerated and the data supports the use of RPL554 in a twice daily dosing
regimen. There were no reports of serious adverse events and fewer adverse
events were seen with RPL554 than with salbutamol. Salbutamol produced
well-acknowledged adverse events for this drug including tremor, tachycardia,
palpitations, and a reduction in blood potassium levels. The large dosing range
(60 fold) of RPL554 suggests a potentially large therapeutic index.'

1 Very significant results - even at the lowest dose - compared to a placebo. Big Pharma will definitely note that.

2 Twice daily dosing regime supported by the data. Very convenient for patients.

3 No serious side effects even at the highest doses. Compare with the known - and not insignificant adverse effects of Salbutomol.

4 Dosing range - 60 fold! - means there's plenty of scope to use/combine RPL554 in a number of therapeutic situations.

All in all very positive results from this study which bodes well for the results from further studies expected later this year. Well done VRP!

vasilis
15/3/2016
08:09
May be looking for new highs???
senor_sensible
15/3/2016
07:45
Bronchodilator effect as good as Salbutamol with fewer adverse effects ! Wow that statement in itself is amazing.....not even mentioning the anti inflammatory effect!.....starting to look exceptionally promising
shearluc
15/3/2016
07:23
Nice RNS this morning :-)
senor_sensible
15/3/2016
07:20
Fantastic results
aimshares
15/3/2016
07:17
Verona Pharma plc("Verona Pharma" or the "Company")Verona Pharma reports positive results from RPL554 dose-finding studyStudy demonstrates drug has substantial bronchodilator effect and excellent tolerability at broad range of dosesData continues to suggest drug could be meaningful new addition, alone or in combination, for the treatment of COPD15 March 2016, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces positive headline data from a Phase IIa dose-finding clinical study using the Company's new proprietary nebulised formulation of RPL554. RPL554 is a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule, currently in development as a nebulised treatment for acute exacerbations in chronic obstructive pulmonary disorder (COPD) patients in a hospital or home-care setting. Such patients typically require additional bronchodilation as well as anti-inflammatory treatment despite being on maximum doses of approved COPD medications (which often contain salbutamol).HighlightsPrimary objective of study metNebulised RPL554 demonstrated a dose-dependent bronchodilator response in asthma patients; the response was highly statistically significant (p
aimshares
15/3/2016
07:16
RNS out Great results
aimshares
11/3/2016
09:45
the efforts web site folks is old but well worth a nosey if u wanna learn about copd either as a patient or interest re copd drugs and understanding so well worth a read.....

i been a member for 12 years and its helped me to get eductaed and self survive the dammn disease, knolwedge and empowerment is everything
dyor etc of course

corbine
11/3/2016
09:43
yeh if u go to efforts copd website youll see lots of patients have craappy side effects from rof and breo and other so called leading copd meds.
role on 554 no side effects that are on par with whats out there so win win thus far eh?
not forgetting they tried a 16 times dose and still no sides, which is remarkable for a drug of this type (rpl554)
3 sets of news due over coming 10 weeks according to video released on sprojets and also now on u tube, although not easy to hear
(pump up the volume)
regards
corbs:-)
(ps efforts website is a voluntary one running for over 15 years and relies on donations) all moderators etc are voluntary and all suffering from copd, some are double lung transplant survivors.
there is a wealth of information regarding copd on there, how to live with it as a patient, coping startegies, chat room, and even daily updates from one moderator via email on anything they find out in web world to do with drugs coming out, trials etc relative to copd

corbine
11/3/2016
08:39
Phosphodiesterase Inhibitors

Roflumilast was the first phosphodiesterase inhibitor (PDEi) other than theophylline to be approved for chronic obstructive pulmonary disease (COPD). However, its propensity to produce undesirable side effects, principally gastro-intestinal ones, has hampered its widespread use. But that agent has anti-inflammatory actions, at least in vitro, as well as its Food and Drug Administration- approved indication to reduce the frequency of acute exacerbations of COPD. Roflumilast provided proof of concept for the development of several other PDE’s for COPD. Several pharmaceutical companies have targeted COPD with novel phosphodiesterase inhibitors to meet the large and unmet needs of COPD patients. The well-known PDE5 inhibitors, sildenafil, tadalafil and udenafil, appear to have little or no beneficial action on the airways of COPD patients.1,2 But several novel PDE4 antagonists are in development. They are discussed below.
RPL554

RPL554 is an interesting example. Verona Pharm’s lead product is a phosphodiesterase inhibitor that inhibits both PDE3 and PDE4. It is being developed for asthma and cystic fibrosis as well as COPD.3,4 The drug is novel both in that it can be delivered by inhalation and it inhibits 2 relevant phosphodiesterase inhibitors. The PDE3 component relaxes airway smooth muscle, and the PDE4 component inhibits the activation and release of inflammatory mediators. RPL554 has been effective and well tolerated in one small proof-of-concept study5 and is now entering a Phase II trial (NCT02542254). In a six-arm crossover study, 30 individuals with COPD will receive placebo or short-acting albuterol or ipratropium or combinations of these in addition to a single dose of RPL554.6

peawacks
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older

Your Recent History

Delayed Upgrade Clock